Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Reviews Options For European Business, Adopts New Manufacturing Processes

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline will implement a new £1.5 billion restructuring program to improve commercial efficiencies in Europe and adopt new manufacturing processes, following sales and profits shortfalls in 2012.

You may also be interested in...



U.S. Biotechs Strike Out Across Europe

U.S. biotech companies are showing greater interest in building commercial infrastructure in Europe, in order to bring new medicines to European customers without local partners. Switzerland is a popular location, because of its position in the center of the continent, but the presence of experienced management is also important.

GSK Bundles Legacy Drugs Into Separate Portfolio In Housekeeping Move

GlaxoSmithKline is bundling around 50 legacy drugs comprising some £3 billion ($4.6 billion) in annual sales into a standalone global portfolio, in a “housekeeping” move that Britain’s biggest medicines maker says is needed to better prepare the group for its coming wave of new product launches.

In Brief

WHO GMP revisions proposed; ICH M7 guide drafted; four CEPs withdrawn; 28th China plant added to FDA’s import alert list.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel